Relapse often leads to difficulties in MM treatment, as patients may have developed resistance to a previous therapy. While the European Society for Medical Oncology (ESMO) provides some guidelines to determine what types of therapy are recommended for relapsed patients, Francesca Gay, MD, of University of Turin, Turin, Italy, explains why these guidelines may not always be suitable. Dr Gay mentions several criteria that must be considered when determining the first post-relapse course of treatment, and other side effects that these new treatments could lead to. This interview took place at the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy.
